BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund that invests in the healthcare industry. The fund seeks to provide a high level of income and capital appreciation by investing in equity securities of companies in the healthcare sector, including pharmaceutical, biotechnology, medical device, healthcare services, and healthcare technology companies.
BMEZ was launched on August 26, 2020, and is managed by BlackRock Advisors, LLC. The fund has a total net asset value of approximately $350 million and trades on the New York Stock Exchange.
BMEZ's investment strategy is focused on identifying companies with strong growth potential that operate in attractive markets, have a competitive advantage, and a strong financial position. The fund invests in both U.S. and non-U.S. companies, with a majority of its assets invested in large-cap companies.
BMEZ's portfolio is well diversified across different sub-sectors of healthcare. As of December 31, 2021, the fund had 97 holdings, with its top ten holdings accounting for approximately 41% of its portfolio. Some of the fund's largest holdings include Johnson & Johnson, Amgen Inc., and Thermo Fisher Scientific Inc.
In terms of performance, BMEZ has had a strong start since its launch. As of December 31, 2021, the fund's net asset value had increased by approximately 29% since inception, and it had generated a distribution yield of 6.04%. However, it is important to note that past performance is not indicative of future results, and there are risks associated with investing in closed-end funds, such as the possibility of a discount or premium to net asset value, as well as market and industry-specific risks.
Overall, BMEZ is a healthcare-focused closed-end fund that seeks to provide investors with both income and capital appreciation. Its diversified portfolio and strong management team make it an attractive option for investors looking to gain exposure to the healthcare sector.
|
